Subscribe to Search results

For years, it was considered that because domestic blood products were manufactured by agents of the Crown, Crown immunity rendered domestic products free of similar controls.

Published on:

Mr Wormald favoured the expansion of PFC as well as rebuilding Elstree.

Published on:

A paper by the Economic Advisors' Office concluded that the most economic option available to meet the NBS' demand for blood products was to redevelop BPL.

Published on:

A briefing paper on Blood Products Laboratory Redevelopment said that "Given that the present BPL has to be redeveloped ... it would be more expensive to build a smaller BPL (£18.6 million) and invest £4 million in PFC than to build a BPL capable of achieving self-sufficiency (£21.03 million)."

Published on:

Freeze-dried fractions made from human blood were developed by Kekwick and Wolf, Soulier, Blombäck and others.

Published on:

Dr Antonio Fernández-Montoya argued in a paper that blood donation was an example of genuine altruism where the altruistic behaviour was incorporated into the self as a role.

Published on:

John Canavan wrote to the Scottish Home and Health Department to notify them of the decision to undertake a pilot testing study of anti-HCV screening.

Published on:

Dr Gunson circulated a report on Phase I of the multi-centre anti-HCV trial to Dr Rejman for the attention of the ACVSB.

Published on:

In a letter from Dr Peter Kernoff to Dr Brian Colvin, NANBH was described as a serious disease with significant long-term consequences.

Published on:

NANBH was described as already becoming "a major source of concern" in a minute regarding the establishment of an advisory group on viral hepatitis.

Published on:

In a brief circulated by Dr Metters in advance of an ACVSB meeting, he noted that the main issue for the Committee in relation to non-A non-B Hepatitis was "whether the time is right to make a decision about adopting the Chiron test".

Published on:

Dr Pickles wrote to Dr Rejman and John Canavan emphasising that they "must not delay in seeking help elsewhere in the department in refining our assessment of the cost-benefit of hepatitis C screening."

Published on:

Dr Metters asked Dr Rejman and John Canavan to provide "the best available data on the sensitivity, specificity and predictive value of the Ortho and RIBA tests".

Published on:

The finalised ministerial submission on hepatitis screening outlined arguments for and against introduction. Although it would not be implemented for several months, the minister was asked to agree that it should be introduced and recommended that preparations should be made to introduce it as soon as practicable.

Published on:

George Hart wrote to Sir Robert McCrindle expressing concerns about the cost of the proposed anti-HCV screening.

Published on:

John Canavan circulated the first draft submission recommending the introduction of anti-HCV screening.

Published on:

Dr Mortimer of PHLS wrote to Dr Rejman noting that the case for Hepatitis C virus antibody testing was very strong, and that the UK should screen universally once the Ortho test and/or Abbott test was approved by the FDA in USA. He noted that they would otherwise be in a weak position if cases of transmission rose.

Published on:

The preliminary findings of the NBTS three-centre study showed that 11 of 3,032 samples from Bristol (0.36%), 25 of 3,642 samples from Manchester (0.69%) and 25 of 3,010 samples from North London (0.83%) repeatedly tested positive for anti-HCV.

Published on:

The preliminary findings of the NBTS three-centre study showed that anti-HCV positivity indicated that a patient was suffering from non-A non-B Hepatitis, and that the test was detecting a viral marker associated with NANBH. The findings also included that, in general, 70-80% of patients suffering from treated (or severe) haemophilia were anti-HCV positive.

Published on:

A Spanish study reported that approximately 60% of recipients of anti-HCV positive donor blood would go on to develop NANBH.

Published on: